title: Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect?
authors.forename: Daniel
authors.initials: D
authors.lastname: Wendling
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Dernis
authors.forename: Clément
authors.initials: C
authors.lastname: Prati
authors.forename: Eric
authors.initials: E
authors.lastname: Frisch
authors.forename: Bernard
authors.initials: B
authors.lastname: Delbosc
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005128:Eye Diseases / Q000139:chemically induced*; D006801:Humans; D007249:Inflammation / Q000139:chemically induced; D008297:Male; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D019947:Receptors, Interleukin-6; C502936:tocilizumab